.RESEARCH STUDY EMPHASIZE.16 October 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to standard procedure for muscle-invasive sac cancer cells boosted event-free and overall survival, marking a brand-new procedure choice for this health condition.